• In May, Lexaria made a number of positive announcements related to its R&D initiatives
• In addition to holding its 2023 Annual Meeting, the company completed dosing for its human clinical nicotine study, NIC-H22-1
• Lexaria also reported 900% improvements in delivery of DehydraTECH(TM) processed estrogen into blood plasma in an animal study
• In a human hypertension study, the comfpany announced that its DehydraTECH-CBD formulation resulted in significant reductions in the blood plasma levels of pro-inflammatory biomarkers (IL 8, 10, and 18)
• These biomarkers are linked to cardiovascular disease (“CVD”) and many other conditions, such as asthma, lung diseases, chronic kidney disease, fatty liver disease, Type 1 and 2 diabetes, obesity, and rheumatoid arthritis

“If you’ve been following Lexaria for any period of time, you know that applied R&D is our lifeblood. It helps us establish areas of investigation for commercial pursuits, reduces risks of the unknown for both commercial and regulatory goals, and more,” wrote Lexaria CEO Chris Bunka in the January 2023 annual letter (https://ibn.fm/XQswm).

A look at the company’s announcements throughout May shows its unwavering resolve to support its lifeblood and, in the process, gain additional knowledge and understanding of the limitations and capabilities of its patented DehydraTECH(TM) technology. The company started the month off with the announcement that it had completed dosing in its human clinical nicotine Study, NIC-H22-1.

With data showing that cigarette smoking claims the lives of more than 7 million people per year globally, Lexaria conducted the study as part of its efforts to validate its reduced-risk technology, which is poised to potentially provide tobacco smokers with a safer and faster-acting source of purified nicotine that delivers nicotine into blood plasma faster, potentially satisfying cravings more quickly. The study evaluated the capabilities of the company’s DehydraTECH-processed oral nicotine formulation by comparing it with the performance of other commercially available oral nicotine pouches sold under the On! and Zyn brands. Lexaria will provide further updates and any relevant material findings as they become available (https://ibn.fm/PYLeS).

Lexaria also reported the completion of its animal study HOR-A22-1, demonstrating its DehydraTECH(TM) platform technology significantly enhanced the oral delivery of estradiol, a type of estrogen hormone that is used in therapeutic products in women’s health sector (https://ibn.fm/HAL2x). Performed in 20 female Sprague-Dawley rats, the study compared a DehydraTECH-estradiol formulation to a generic estradiol composition.

The study aimed to evaluate the ability of DehydraTECH to enhance the delivery properties of the orally administered hormone using parameters such as Cmax, the maximum concentration in the bloodstream, and area under the curve (“AUC”), a measure that gives insight into the total delivery of estradiol over time and the extent of exposure to estrone. (Estrone is a second type of estrogen that is reversibly manufactured from estradiol in tissues found in the mammary gland, uterus, and liver.)

The animal study HOR-A22-1 found that the DehydraTECH-estradiol formulation resulted in a Cmax about 900% higher than the control formulation’s. Additionally, the AUC readings for estradiol and estrone when the DehydraTECH-processed composition was used were 1,500% and 12,500% higher, respectively, than when the control was used.

More specifically, after five weeks of treatment, the DehydraTECH-CBD formulation resulted in a 19%, 27%, and 43% reduction in the blood plasma levels of IL 8, 10, and 18, respectively. “There is some pre-clinical evidence for the anti-inflammatory actions of CBD, but this is likely the most convincing evidence in humans that I have ever seen,” Dr. Philip Ainslie, Cardiovascular Advisor to Lexaria and Lead Investigator of the study, said of the results.

In non-R&D-related news, the company reported the closing of its public offering, which generated approximately $2.0 million in gross proceeds (https://ibn.fm/CZgk2).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.comw
480.374.1336 Office
[email protected]

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

The post Lexaria Bioscience Corp.’s (NASDAQ: LEXX) May Announcements Show Resolve to Continue Supporting R&D ‘Lifeblood’ appeared first on QualityStocks.